Just saw Celldex dropped some solid data on their urticaria treatment at the AAAAI conference. Barzolvolimab seems to be holding up pretty well in retreatment scenarios for cold urticaria and dermographism patients. So basically if symptoms come back, you can treat again and get the same level of control as the first time around - that's actually pretty useful for a chronic condition.

What caught my attention is that the safety profile stayed consistent and patients got rapid relief from the usual urticaria stuff like hives and itching. They're running a Phase 3 program called EMBARQ to validate this further. CLDX has been bouncing around the $14-31 range over the past year, closed at $30.09 Friday and popped up to $30.47 in after-hours. The retreatment angle is interesting because it means you're not stuck with continuous dosing if symptoms flare up periodically.

Not sure if this moves the needle long-term but for patients dealing with chronic urticaria, having a therapy you can cycle back to seems like a solid option. Biotech data reads can be hit or miss but this one looks pretty straightforward.